Inflammatory Bowel Disease and Risk of Ischemic Heart Disease: An Updated Meta-Analysis of Cohort Studies.
Inflammatory Bowel Disease and Risk of Ischemic Heart Disease: An Updated Meta-Analysis of Cohort Studies.
复制标题
DOI：
10.1161/jaha.117.005892
复制
发表时间：
2017-08-02
影响因子：
5.4
通讯作者：
Shen H
中科院分区：
文献类型：
--
作者：
Feng W;Chen G;Cai D;Zhao S;Cheng J;Shen H
几种免疫介导的疾病已被证明与心血管疾病风险增加有关。然而，评估炎症性肠病和心血管疾病风险之间关系的研究报告了不一致的结果。我们在队列研究的Meta分析中评估了炎症性肠病与缺血性心脏病风险之间的关系。我们对截至2016年10月的PubMed和Embase进行了文献检索，以识别相关研究。使用随机效应模型计算汇总相对风险。为了探讨异质性的来源，我们进行了亚组和敏感性分析。我们纳入了10项符合纳入标准的队列研究。炎症性肠病患者与缺血性心脏病风险增加相关（相对风险：1.244; 95%CI，1.142-1.355）。观察到相当大的异质性。克罗恩病显示缺血性心脏病的风险显著增加（相对风险=1.243; 95%CI，1.042-1.482），溃疡性结肠炎也观察到正相关（相对风险=1.206; 95%CI，1.170-1.242）。基于队列研究的Meta分析，我们发现炎症性肠病患者缺血性心脏病的风险增加。大型长期前瞻性研究是必要的，以证实我们的结果。
Several immune‐mediated diseases have been shown to be associated with an increased risk of cardiovascular disease. However, studies evaluating the association between inflammatory bowel disease and risk of cardiovascular disease reported inconsistent results. We assessed the association between inflammatory bowel disease and risk of ischemic heart disease in a meta‐analysis of cohort studies. We conducted a literature search of PubMed and Embase up to October 2016 to identify relevant studies. The summary relative risks were calculated using the random‐effects models. To explore the source of heterogeneity, we performed subgroup and sensitivity analysis. We included 10 cohort studies that satisfied our inclusion criteria. Patients with inflammatory bowel disease were associated with an increased risk of ischemic heart disease (relative risk: 1.244; 95% CI, 1.142–1.355). Considerable heterogeneity was observed. Crohn's disease showed a significantly increased risk of ischemic heart disease (relative risk=1.243; 95% CI, 1.042–1.482) and a positive association was also observed in ulcerative colitis (relative risk=1.206; 95% CI, 1.170–1.242). Based on meta‐analysis of cohort studies, we found an increased risk of ischemic heart disease in patients with inflammatory bowel disease. Large long‐term prospective studies are warranted to confirm our results.